Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Hanx Biopharmaceuticals (Wuhan) Co Current Ratio?
Hanx Biopharmaceuticals (Wuhan) CoHKSE:03378 +6.00%11 Current Ratio is 7.27 as of Dec. 2025, which is 53% above its 10-year median of 4.75. GuruFocus rates HKSE:03378 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, Hanx Biopharmaceuticals (Wuhan) Co ranks better than 69.45% on this metric.
Hanx Biopharmaceuticals (Wuhan) Co has a current ratio of 7.27. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
HKSE:03378'
s Current Ratio Range Over the Past 10 Years
Min: 1.23 Med: 4.75 Max: 7.27
Current: 7.27
During the past 3 years, Hanx Biopharmaceuticals (Wuhan) Co's highest Current Ratio was 7.27. The lowest was 1.23. And the median was 4.75.
HKSE:03378's Current Ratio is ranked better than 69.45% of 1411
companies
in the Biotechnology industry
Industry Median: 3.85
vs HKSE:03378: 7.27
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Hanx Biopharmaceuticals (Wuhan) Co Current Ratio Related Terms
Hanx Biopharmaceuticals (Wuhan) Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hanx Biopharmaceuticals (Wuhan) Co Current Ratio Chart
Hanx Biopharmaceuticals (Wuhan) Co Annual Data
Trend
Dec23
Dec24
Dec25
Current Ratio
4.75
1.23
7.27
Hanx Biopharmaceuticals (Wuhan) Co Semi-Annual Data
Dec23
Dec24
Dec25
Current Ratio
4.75
1.23
7.27
HKSE:03378 vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Hanx Biopharmaceuticals (Wuhan) Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hanx Biopharmaceuticals (Wuhan) Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hanx Biopharmaceuticals (Wuhan) Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Hanx Biopharmaceuticals (Wuhan) Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a Current Ratio of 7.27 as of Dec. 2025. This is 53% above median its historical median of 4.75. Over the past decade, Hanx Biopharmaceuticals (Wuhan) Co's Current Ratio has ranged from 1.23 to 7.27. According to the industry distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #431 out of 1411 companies in the Biotechnology industry, placing it in the top 30.5%.
Is Hanx Biopharmaceuticals (Wuhan) Co's Current Ratio too high?
Hanx Biopharmaceuticals (Wuhan) Co's current Current Ratio of 7.27 is 53% above median its 10-year median of 4.75. Over the past 10 years, this metric has ranged from a low of 1.23 to a high of 7.27. The Biotechnology industry median Current Ratio is 3.85. Hanx Biopharmaceuticals (Wuhan) Co's value of 7.27 is 88.8% above this industry median. Based on the distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #431 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hanx Biopharmaceuticals (Wuhan) Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hanx Biopharmaceuticals (Wuhan) Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #431 out of 1411 companies for Current Ratio. This puts Hanx Biopharmaceuticals (Wuhan) Co in the upper half of its industry. The industry median Current Ratio is 3.85. Hanx Biopharmaceuticals (Wuhan) Co's value of 7.27 is 88.8% above this benchmark. Historically, Hanx Biopharmaceuticals (Wuhan) Co's own Current Ratio has ranged from 1.23 to 7.27 over the past decade. While the company's 10-year median is 4.75 vs. the industry median of 3.85, Hanx Biopharmaceuticals (Wuhan) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hanx Biopharmaceuticals (Wuhan) Co's current Current Ratio of 7.27 is 88.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hanx Biopharmaceuticals (Wuhan) Co's current Current Ratio is 7.27, which is 53% above median its own 10-year median of 4.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hanx Biopharmaceuticals (Wuhan) Co stock overvalued right now?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a current Current Ratio of 7.27. The current Current Ratio is 7.27, which is 53% above median its 10-year median of 4.75 and 88.8% above the Biotechnology industry median of 3.85. Hanx Biopharmaceuticals (Wuhan) Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378), the current Current Ratio is 7.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hanx Biopharmaceuticals (Wuhan) Co Business Description
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
11GF Score
Get the complete analysis for HKSE:03378
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03378 has been successfully added to your 
